<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>Hypercholesterolemia (Hyperlipidemia) | Family Medicine Reference</title>
  <style>
    body {
      font-family: "Segoe UI", Tahoma, Geneva, Verdana, sans-serif;
      background-color: #f8f9fa;
      color: #212529;
      line-height: 1.6;
      margin: 40px;
    }
    h1, h2, h3 {
      color: #004085;
    }
    section {
      background: #ffffff;
      border-radius: 8px;
      box-shadow: 0 2px 5px rgba(0,0,0,0.1);
      padding: 25px;
      margin-bottom: 20px;
    }
    table {
      width: 100%;
      border-collapse: collapse;
      margin: 15px 0;
    }
    th, td {
      border: 1px solid #dee2e6;
      padding: 10px;
      text-align: left;
    }
    th {
      background-color: #e9ecef;
    }
    .source {
      font-size: 0.9em;
      color: #555;
    }
    a {
      color: #0069d9;
      text-decoration: none;
    }
    a:hover {
      text-decoration: underline;
    }
  </style>
</head>
<body>

  <h1>Hypercholesterolemia (Hyperlipidemia)</h1>

  <section>
    <h2>Definition</h2>
    <p>
      <strong>Dyslipidemia</strong> refers to abnormal concentrations of lipids in the blood.  
      <strong>Hyperlipidemia</strong> indicates elevated levels of cholesterol and/or triglycerides.
    </p>
    <ul>
      <li><strong>Hypercholesterolemia:</strong> Elevated total or LDL cholesterol</li>
      <li><strong>Hypertriglyceridemia:</strong> Elevated triglycerides</li>
      <li><strong>Mixed hyperlipidemia:</strong> Both cholesterol and triglycerides elevated</li>
    </ul>
  </section>

  <section>
    <h2>Etiology</h2>
    <table>
      <tr><th>Category</th><th>Examples</th></tr>
      <tr>
        <td><strong>Primary (genetic)</strong></td>
        <td>Familial hypercholesterolemia, familial combined hyperlipidemia, polygenic hypercholesterolemia</td>
      </tr>
      <tr>
        <td><strong>Secondary (acquired)</strong></td>
        <td>
          Uncontrolled diabetes mellitus, hypothyroidism, nephrotic syndrome, chronic kidney disease, Cushing syndrome, alcohol use, obesity, medications (e.g., corticosteroids, thiazides, antiretrovirals)
        </td>
      </tr>
    </table>
  </section>

  <section>
    <h2>Screening</h2>
    <ul>
      <li><strong>Adults:</strong> Begin at age 20; repeat every 4–6 years if normal (per ACC/AHA).</li>
      <li><strong>High-risk groups:</strong> Family history of premature ASCVD, diabetes, hypertension, obesity — screen earlier and more frequently.</li>
      <li><strong>Children:</strong> Universal screening once between ages 9–11 and 17–21 (for familial forms).</li>
    </ul>
  </section>

  <section>
    <h2>Clinical Features</h2>
    <ul>
      <li>Usually asymptomatic</li>
      <li><strong>Xanthomas:</strong> yellow papules over tendons or skin</li>
      <li><strong>Xanthelasma:</strong> cholesterol deposits on eyelids</li>
      <li><strong>Corneal arcus:</strong> white/gray ring around cornea (early sign in familial hypercholesterolemia)</li>
      <li>Complications: atherosclerosis → coronary artery disease, stroke, peripheral vascular disease</li>
    </ul>
  </section>

  <section>
    <h2>Diagnosis</h2>
    <ul>
      <li><strong>Lipid panel:</strong> fasting or non-fasting (total cholesterol, LDL, HDL, triglycerides)</li>
      <li><strong>LDL calculation:</strong> LDL = Total cholesterol − HDL − (Triglycerides/5)</li>
      <li>Consider secondary causes with: fasting glucose, TSH, liver and renal function tests</li>
    </ul>
  </section>

  <section>
    <h2>Treatment</h2>

    <h3>1. Lifestyle Modifications (for all patients)</h3>
    <ul>
      <li>Diet: reduce saturated fats, trans fats, and cholesterol intake</li>
      <li>Increase fiber, fruits, vegetables, and omega-3 intake</li>
      <li>Regular aerobic exercise (≥150 min/week)</li>
      <li>Weight control and smoking cessation</li>
      <li>Limit alcohol intake</li>
    </ul>

    <h3>2. Pharmacologic Therapy</h3>
    <table>
      <tr><th>Drug Class</th><th>Examples</th><th>Main Effects / Notes</th></tr>
      <tr>
        <td><strong>Statins (HMG-CoA reductase inhibitors)</strong></td>
        <td>Atorvastatin, Rosuvastatin, Simvastatin</td>
        <td>↓ LDL 30–60%; first-line for ASCVD prevention; monitor LFTs and myopathy</td>
      </tr>
      <tr>
        <td><strong>Ezetimibe</strong></td>
        <td>—</td>
        <td>↓ LDL 15–25%; add if statin alone insufficient or statin intolerance</td>
      </tr>
      <tr>
        <td><strong>PCSK9 inhibitors</strong></td>
        <td>Evolocumab, Alirocumab</td>
        <td>Potent LDL reduction (~60%); for familial or refractory hypercholesterolemia</td>
      </tr>
      <tr>
        <td><strong>Bile acid sequestrants</strong></td>
        <td>Cholestyramine, Colesevelam</td>
        <td>↓ LDL; may ↑ triglycerides; safe in pregnancy</td>
      </tr>
      <tr>
        <td><strong>Fibrates</strong></td>
        <td>Fenofibrate, Gemfibrozil</td>
        <td>↓ Triglycerides; avoid combining Gemfibrozil with statins</td>
      </tr>
      <tr>
        <td><strong>Niacin</strong></td>
        <td>—</td>
        <td>↑ HDL, ↓ LDL and triglycerides; limited by flushing, hyperglycemia</td>
      </tr>
      <tr>
        <td><strong>Omega-3 fatty acids</strong></td>
        <td>Icosapent ethyl</td>
        <td>↓ Triglycerides; used in severe hypertriglyceridemia</td>
      </tr>
    </table>

    <h3>3. Treatment Targets</h3>
    <ul>
      <li><strong>Severe LDL elevation (≥190 mg/dL):</strong> High-intensity statin</li>
      <li><strong>Familial hypercholesterolemia:</strong> LDL goal &lt; 100 mg/dL (or &lt; 70 mg/dL if ASCVD)</li>
      <li><strong>High triglycerides (&gt;500 mg/dL):</strong> Fibrates or omega-3s to prevent pancreatitis</li>
    </ul>

    <h3>4. Follow-Up</h3>
    <ul>
      <li>Repeat lipid panel 6–12 weeks after initiation or dose change</li>
      <li>Monitor liver enzymes and muscle symptoms</li>
      <li>Reassess cardiovascular risk and adherence regularly</li>
    </ul>
  </section>

  <section>
    <h2>Familial Hypercholesterolemia (FH)</h2>
    <ul>
      <li>Autosomal dominant disorder → defective LDL receptor</li>
      <li>LDL typically &gt; 190 mg/dL in adults</li>
      <li>Early-onset CAD, tendon xanthomas, corneal arcus</li>
      <li>Treatment: maximal statin + ezetimibe ± PCSK9 inhibitor; consider LDL apheresis in homozygous FH</li>
    </ul>
  </section>

  <section>
    <h2>Severe Hypertriglyceridemia</h2>
    <ul>
      <li>Triglycerides &gt; 500 mg/dL → risk of pancreatitis</li>
      <li>Treat secondary causes (alcohol, diabetes, drugs)</li>
      <li>Start fibrate ± omega-3 fatty acids</li>
      <li>Add niacin or statin if LDL elevation coexists</li>
    </ul>
  </section>

  <section>
    <h2>Xanthomas and Xanthelasma</h2>
    <ul>
      <li>Cutaneous manifestations of lipid accumulation</li>
      <li>May regress with lipid control, but often recur</li>
      <li>Removal (laser/surgical) for cosmetic purposes</li>
    </ul>
  </section>

  <!-- ======================================= -->
  <!-- NEW SECTION: CARDIOVASCULAR RISK TOOL -->
  <!-- ======================================= -->
  <section>
    <h2>Cardiovascular Risk Calculator (ASCVD) & Statin Therapy Decision Guide</h2>

    <h3>1. ASCVD 10-Year Risk Estimation</h3>
    <ul>
      <li>Use the <a href="https://www.mdcalc.com/calc/3398/ascvd-atherosclerotic-cardiovascular-disease-2013-risk-calculator-aha-acc" target="_blank">ASCVD-Risk-calculator-2013(ACC/AHA)</a>.</li>
      <li>Includes: age, sex, race, total & HDL cholesterol, systolic BP, diabetes, smoking status, and BP treatment.</li>
    </ul>

    <h3>2. Statin Therapy Recommendations (ACC/AHA 2018)</h3>
    <table>
      <tr><th>Risk Group / Condition</th><th>Recommendation</th></tr>
      <tr>
        <td><strong>Clinical ASCVD</strong></td>
        <td>High-intensity statin (goal ≥50% LDL reduction)</td>
      </tr>
      <tr>
        <td><strong>LDL ≥ 190 mg/dL</strong></td>
        <td>High-intensity statin; consider PCSK9 inhibitor if not controlled</td>
      </tr>
      <tr>
        <td><strong>Diabetes (age 40–75)</strong></td>
        <td>Moderate- to high-intensity statin regardless of calculated risk</td>
      </tr>
      <tr>
        <td><strong>No diabetes, age 40–75, LDL 70–189 mg/dL</strong></td>
        <td>
          Base on 10-year ASCVD risk:<br>
          • &lt;5%: lifestyle only<br>
          • 5–7.5%: consider moderate statin<br>
          • 7.5–20%: moderate to high statin<br>
          • &gt;20%: high-intensity statin
        </td>
      </tr>
      <tr>
        <td><strong>Adults &gt;75 years</strong></td>
        <td>Individualized decision based on benefit vs. risk</td>
      </tr>
    </table>

    <h3>3. Statin Intensity (Typical Dosing)</h3>
    <table>
      <tr><th>Intensity</th><th>Statin Examples</th></tr>
      <tr>
        <td><strong>High</strong></td>
        <td>Atorvastatin 40–80 mg, Rosuvastatin 20–40 mg</td>
      </tr>
      <tr>
        <td><strong>Moderate</strong></td>
        <td>Atorvastatin 10–20 mg, Rosuvastatin 5–10 mg, Simvastatin 20–40 mg, Pravastatin 40–80 mg</td>
      </tr>
      <tr>
        <td><strong>Low</strong></td>
        <td>Simvastatin 10 mg, Pravastatin 10–20 mg, Lovastatin 20 mg</td>
      </tr>
    </table>

    <h3>4. Monitoring & Follow-up</h3>
    <ul>
      <li>Recheck lipids 6–12 weeks after therapy initiation or adjustment.</li>
      <li>Assess adherence and tolerance at every visit.</li>
      <li>Recalculate ASCVD risk every 4–6 years in adults 20–79 years without ASCVD.</li>
    </ul>
  </section>

  <p class="source">
    Sources:<br>
    <a href="https://www.amboss.com/us/knowledge/lipid-disorders?utm_medium=chatgpt-plugin&utm_source=chatgpt" target="_blank">AMBOSS: Lipid Disorders</a><br>
    <a href="https://www.mdcalc.com/calc/3398/ascvd-atherosclerotic-cardiovascular-disease-2013-risk-calculator-aha-acc" target="_blank">ASCVD-Risk-calculator-2013(ACC/AHA)</a><br>
    <a href="https://www.amboss.com/us/knowledge/hypothyroidism?utm_medium=chatgpt-plugin&utm_source=chatgpt" target="_blank">AMBOSS: Hypothyroidism</a>
  </p>

</body>
</html>